1:30 PM
 | 
Nov 10, 2017
 |  BC Week In Review  |  Financial News  |  Completed Offerings

NEA, Versant back ophthalmic play Oyster Point with $22M A round

On Nov. 7, ophthalmic play Oyster Point Pharmaceuticals Inc. (San Francisco, Calif.) raised $22 million in a series A round led by New Enterprise Associates and Versant Ventures. Oyster Point President and CEO Jeffrey Nau told BioCentury he expects the funding...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >